Abstract
There is general agreement, including from the pharmaceutical industry, that current market based methods of generating research into the development of pharmaceutical products that are relevant for developing countries do not work. This conclusion is relevant not just for the most neglected diseases such as leishmaniasis but even for global diseases such as cancer and cardiovascular disease. Stimulating research will mean overcoming barriers such as patent thickets, poor coordination of research activities, exclusive licensing of new technologies by universities and the structural problems that inhibit conducting appropriate clinical trials in developing countries. In addition, it is necessary to ensure that the priorities for research reflect the needs of developing countries and not just donors. This article will explore each of these issues and then look at three emerging approaches to stimulating research -paying for innovation, priority review sales or vouchers and public-private partnerships, - and evaluate their strengths and weaknesses. All of the stakeholders agree that there is a pressing need for a major expansion in the level of R&D. Whatever that new model turns out to be, it will have to deal with the 5 barriers ...Continue Reading
References
Jun 6, 1992·BMJ : British Medical Journal·P C WallerM D Rawlins
May 23, 1998·Science·M A Heller, R S Eisenberg
May 3, 2000·JAMA : the Journal of the American Medical Association·S R HillD A Henry
Sep 16, 2000·Breast Cancer Research and Treatment·X DuD A Syblik
Sep 30, 2000·PharmacoEconomics·A H Anis, Y Gagnon
Mar 5, 2003·Age and Ageing·William MacLennan
Feb 12, 2004·Journal of Medical Ethics·A A HyderL Dawson
Aug 9, 2005·Lancet·Anne-Emanuelle Birn
Feb 24, 2006·PLoS Medicine·Merrill Goozner
Apr 13, 2006·PLoS Medicine·Dave A Chokshi
May 16, 2006·Lancet·Pierre Chirac, Els Torreele
May 20, 2006·Bulletin of the World Health Organization·Tomris Türmen, Charles Clift
Sep 21, 2006·Health Policy and Planning·Jeremy Shiffman
Oct 24, 2006·Social Science & Medicine·Kent Buse, Andrew M Harmer
Dec 23, 2006·BMJ : British Medical Journal·Joseph E Stiglitz
Oct 9, 2007·Contemporary Clinical Trials·Sergio Sismondo
May 24, 2008·Science·T J Tucker, M W Makgoba
Nov 6, 2008·Lancet·David StucklerMartin McKee
Nov 7, 2008·The New England Journal of Medicine·Aaron S Kesselheim
Nov 15, 2008·American Journal of Public Health·Bhaven N Sampat
Apr 23, 2009·BMJ : British Medical Journal·Elizabeth Sukkar
May 23, 2009·Public Health Ethics·Thomas Alured Faunce, Hitoshi Nasu
Aug 26, 2009·Bulletin of the World Health Organization·Jeremy Shiffman
Nov 26, 2009·Archives of Internal Medicine·Steven Woloshin, Lisa M Schwartz
Citations
Mar 1, 2013·Open Biology·Elizabeth BilslandStephen G Oliver
Oct 13, 2011·PLoS Neglected Tropical Diseases·Elizabeth BilslandStephen G Oliver
Nov 22, 2011·Future Medicinal Chemistry·Graeme M Robertson, Lorenz M Mayr
Aug 24, 2011·Future Medicinal Chemistry·Stephanie A Robertson, Adam R Renslo
Mar 4, 2014·Global Public Health·Catherine Olivier, Bryn Williams-Jones
Jan 11, 2012·The American Journal of Tropical Medicine and Hygiene·Laura W MusselwhiteEthan Guillen